INFevo, a company specializing in artificial intelligence for scientific applications, has secured over ¥100 million in a Pre-A financing round, marking a record for funding in the virtual cell sector in China. The financing was led by multiple investors, including Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund, and DT Capital, with notable participation from existing shareholders such as Shunwei Capital, HSG, and Songhe Capital. This financing round is the company’s second within five months, following an earlier round that raised tens of millions of RMB in June 2026.
The newly acquired funds will facilitate the development of INFevo’s AI4S infrastructure. The company intends to enhance collaboration in cellular response prediction, scientific hypothesis testing, and high-throughput automated experimental feedback. The goal is to establish a comprehensive AI biology platform that encompasses target discovery, virtual screening, and clinical protocol optimization, ultimately translating advanced computational techniques into precise disease interventions and innovative therapies.
As the application of AI continues to grow in biomedicine, challenges have emerged, particularly concerning the efficiency mismatch in hypothesis generation and experimental verification. INFevo is addressing this issue by employing AI-driven virtual cell models and high-throughput automated laboratories, which aim to improve the process of identifying and testing potential drug candidates.
INFevo has introduced the concept of Recursive Scientific Discovery (RSD), which allows for a structured approach to integrating scientific problems and experimental results. This framework aims to enhance the entire scientific discovery process, enabling continuous improvement in hypothesis generation and experimental design.
Under this framework, INFevo has developed a dual-drive system that combines a foundational large model, OCOO, which predicts cellular responses, with an automated wet experimental system that validates these predictions. The integration of these systems is designed to streamline research processes and enable faster, more effective scientific exploration.
Recently, INFevo has achieved notable success in various research scenarios, including target discovery and virtual screening. The company has launched OCOO-T, a virtual cell foundational model that accurately predicts gene expression changes in response to various experimental perturbations. Additionally, INFevo’s Popper Project (TPP) is an iterative scientific hypothesis mining tool that generates and refines testable hypotheses using advanced AI methodologies.
INFevo’s collaborative efforts extend to partnerships with major clinical institutions, like Peking University First Hospital, aimed at tackling real-world clinical challenges through organoid models and AI analysis.
Lai Lipeng, co-founder and Chief Innovation Officer of INFevo, emphasized the importance of the integration of AI technologies in enhancing our understanding of life sciences. Meanwhile, Zhao Yalong, co-founder of INFevo, expressed gratitude towards investors for their support, highlighting plans to further develop the infrastructure that supports the Recursive Scientific Discovery system.
The funds raised in this financing round will primarily be allocated towards advancing INFevo’s foundational model R&D and expanding its automated experimental systems. The company aims to partner with global pharmaceutical companies and research institutions to enhance drug development processes and contribute to advancements in life sciences.

